Stryker to invest $400m in CMR Surgical

Stryker plans to invest approximately $400 million in British surgical robotics company CMR Surgical through a strategic alliance.

Gains U.S. Sales Rights

Stryker gains exclusive U.S. sales rights to CMR’s Versius robotic surgery systems and an acquisition option.

Preferred Equity Investment

The £300 million preferred equity investment supports Versius portfolio development and global commercialization.

CMR’s Versius System

CMR’s second-generation Versius system uses modular design for soft-tissue surgical procedures in hospitals and ambulatory surgery centers.

Strategic Alliance Details

Stryker serves as exclusive U.S. sales agent while CMR oversees product development outside the United States.

Stryker’s Statement

Stryker’s Andy Pierce says the alliance combines complementary strengths for robotic-assisted surgery adoption.

“We have evaluated the segment carefully for years, and this alliance represents a thoughtful and disciplined entry that combines the complementary strengths of both companies”

CMR’s Statement

CMR’s CEO Massimiliano Colella says Stryker investment accelerates global Versius expansion and welcomes Andy Pierce to board.

“Stryker’s investment will give us additional strength to accelerate innovation and the continued global expansion of the Versius portfolio”